CA2326603A1 - A drug composition containing sodium pravastatin - Google Patents

A drug composition containing sodium pravastatin Download PDF

Info

Publication number
CA2326603A1
CA2326603A1 CA002326603A CA2326603A CA2326603A1 CA 2326603 A1 CA2326603 A1 CA 2326603A1 CA 002326603 A CA002326603 A CA 002326603A CA 2326603 A CA2326603 A CA 2326603A CA 2326603 A1 CA2326603 A1 CA 2326603A1
Authority
CA
Canada
Prior art keywords
drug composition
cellulose
composition according
sodium pravastatin
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002326603A
Other languages
English (en)
French (fr)
Inventor
Man Sik Chang
Woon Sup Lim
Seung Won Suh
Jung Kwon Cha
Jung Min Lee
Jung Joo Kim
Tae Suk Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YUNG JIN PHARMACEUTICAL IND CO Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2326603A1 publication Critical patent/CA2326603A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002326603A 1998-03-31 1999-03-31 A drug composition containing sodium pravastatin Abandoned CA2326603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1998/11172 1998-03-31
KR1019980011172A KR100281521B1 (ko) 1998-03-31 1998-03-31 프라바스타틴나트륨이 함유된 약제 조성물
PCT/KR1999/000157 WO1999049896A1 (en) 1998-03-31 1999-03-31 A drug composition containing sodium pravastatin

Publications (1)

Publication Number Publication Date
CA2326603A1 true CA2326603A1 (en) 1999-10-07

Family

ID=19535615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326603A Abandoned CA2326603A1 (en) 1998-03-31 1999-03-31 A drug composition containing sodium pravastatin

Country Status (7)

Country Link
EP (1) EP1067967A1 (ko)
JP (1) JP2003517432A (ko)
KR (1) KR100281521B1 (ko)
CN (1) CN1298311A (ko)
AU (1) AU3057099A (ko)
CA (1) CA2326603A1 (ko)
WO (1) WO1999049896A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105643A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma Inc. Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658306B2 (ja) * 2000-10-18 2011-03-23 ナガセ医薬品株式会社 錠剤用医薬組成物
WO2003055991A1 (en) * 2001-12-21 2003-07-10 Rigshospitalet Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux
EP1490029A4 (en) * 2002-03-22 2006-02-22 Ranbaxy Lab Ltd DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
US7879821B2 (en) * 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
BG934U1 (bg) * 2006-12-14 2007-11-30 "Софарма" Ад Състав за твърда лекарствена форма, съдържащ правастатин
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
CN101580466B (zh) * 2008-05-12 2012-04-04 上海天伟生物制药有限公司 一种萘维太定的钠盐的制备方法
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
JP6088872B2 (ja) * 2013-03-22 2017-03-01 サラヤ株式会社 ラクトン型ソホロリピッドの分解が抑制されたソホロリピッド粉末

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3223232C2 (de) * 1982-06-22 1984-04-05 Wolfgang Dipl.-Phys. Dr.-Ing. 4800 Bielefeld Lindemann Vorschubeinrichtung an einer mit einem umlaufenden Werkzeug versehenen Maschine, wie Schäl- oder Richtmaschine, für stangenförmiges Material, wie Wellen, Draht, Rohre o.dgl.
DD232198A1 (de) * 1984-07-13 1986-01-22 Jenapharm Veb Verfahren zur herstellung von festen komprimaten
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
TW224049B (ko) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105643A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma Inc. Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor

Also Published As

Publication number Publication date
WO1999049896A1 (en) 1999-10-07
AU3057099A (en) 1999-10-18
EP1067967A1 (en) 2001-01-17
CN1298311A (zh) 2001-06-06
JP2003517432A (ja) 2003-05-27
KR100281521B1 (ko) 2001-02-15
KR19990076302A (ko) 1999-10-15

Similar Documents

Publication Publication Date Title
TW492878B (en) Tablet composition
US6936274B2 (en) Storage stable thyroxine active drug formulations and methods for their production
KR101665395B1 (ko) 6-플루오로-3-히드록시-2-피라진카르복사미드 함유 정제 및 조립분말
KR101409087B1 (ko) 광 안정성이 우수한 의약 제제
CA2326603A1 (en) A drug composition containing sodium pravastatin
RU2643325C2 (ru) Жидкие композиции рацекадотрила
AU2010210123B2 (en) Process for the preparation of a pharmaceutical composition comprising ezetimibe
JPH10330251A (ja) コレステロール低下剤
CN103800322A (zh) 氟伐他汀钠组合物
CN102008477B (zh) 一种瑞舒伐他汀钙片药物组合物的制备方法
US7052717B2 (en) Storage stable thyroxine active drug formulations and methods for their production
FR2904774A1 (fr) Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent.
JP2019011322A (ja) 医薬組成物
JP6990470B2 (ja) レナリドミド胃内滞留型徐放錠及びその調製方法
KR100594606B1 (ko) 속방성 경구 의약품 조성물
KR20090086686A (ko) 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법
FR2839888A1 (fr) Complexes d'inclusion de fenofibrate et de cyclodextrine et composition pharmaceutique les renfermant
US20050069584A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
US20090247603A1 (en) Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP0483320B1 (fr) Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation
JP3947244B2 (ja) 消化性潰瘍治療用製剤
Sharma et al. Formulation and evaluation of controlled release osmotic tablet of carvedilol phosphate
KR100514590B1 (ko) 프라바스타틴나트륨 및 안정화제로서의 코폴리비돈을함유하는 약제 조성물
FR2951945A1 (fr) Composition pharmaceutique
ZA200100828B (en) Compressed compositions comprising clarified xanthan gum.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead